Patents Assigned to ZYNERBA PHARMACEUTICALS
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20240122873
    Abstract: The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.
    Type: Application
    Filed: October 9, 2023
    Publication date: April 18, 2024
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: James Griesser, Thomas W. Dobbins, Terri Sebree
  • PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME
    Publication number: 20240083866
    Abstract: Described herein are ?9-THC prodrugs, methods of making ?9-THC prodrugs, formulations comprising ?9-THC prodrugs and methods of using ?9-THC. One embodiment described herein relates to the transdermal administration of a ?9-THC prodrug for treating and preventing diseases and/or disorders.
    Type: Application
    Filed: August 1, 2023
    Publication date: March 14, 2024
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
  • Cannabidiol for the Treatment of Refractory Seizures
    Publication number: 20240009210
    Abstract: Provided are methods of treating refractory seizures in a human subject, e.g., a child, that include administering an effective amount of cannabidiol (CBD), e.g., in a transdermal gel.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 11, 2024
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Joseph Palumbo, Donna Gutterman, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230414533
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 28, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20230364028
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: March 21, 2023
    Publication date: November 16, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11779549
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 10, 2023
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230059709
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by administering an effective amount of cannabidiol (CBD). Specifically, subjects having moderate to severe ASD and relatively high social avoidance and/or anxiety are more likely to show a reduction in irritability when treated with CBD.
    Type: Application
    Filed: October 20, 2022
    Publication date: February 23, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Joseph Palumbo, Stephen V. O'Quinn, Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
    Publication number: 20230024756
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.
    Type: Application
    Filed: September 30, 2022
    Publication date: January 26, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20230000790
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Application
    Filed: August 24, 2022
    Publication date: January 5, 2023
    Applicants: ZYNERBA PHARMACEUTICALS, INC., ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
    Publication number: 20230000792
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.
    Type: Application
    Filed: September 9, 2022
    Publication date: January 5, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOL
    Publication number: 20230000793
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral and/or psychiatric symptoms of 22q11.
    Type: Application
    Filed: September 9, 2022
    Publication date: January 5, 2023
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • Treatment of 22Q11.2 deletion syndrome with cannabidiol
    Patent number: 11458109
    Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: October 4, 2022
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman
  • Treatment of Fragile X Syndrome with cannabidiol
    Patent number: 11458110
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: October 4, 2022
    Assignee: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Marcel Bonn-Miller, Nancy Tich, Donna Gutterman, John Messenheimer, Terri Sebree
  • TREATMENT OF BEHAVIORAL IMPAIRMENT IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY
    Publication number: 20220218625
    Abstract: The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 14, 2022
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman, John Messenheimer
  • PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME
    Publication number: 20220194916
    Abstract: Described herein are ?9-THC prodrugs, methods of making ?9-THC prodrugs, formulations comprising ?9-THC prodrugs and methods of using ?9-THC. One embodiment described herein relates to the transdermal administration of a ?9-THC prodrug for treating and preventing diseases and/or disorders.
    Type: Application
    Filed: November 24, 2021
    Publication date: June 23, 2022
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard
  • TREATMENT OF AUTISM WITH CANNABIDIOL
    Publication number: 20220096396
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: September 2, 2021
    Publication date: March 31, 2022
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Marcel Bonn-Miller, Donna Gutterman
  • TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL
    Publication number: 20210401769
    Abstract: The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.
    Type: Application
    Filed: June 28, 2021
    Publication date: December 30, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: James Griesser, Thomas W. Dobbins, Terri Sebree
  • TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL
    Publication number: 20210369643
    Abstract: The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.
    Type: Application
    Filed: May 25, 2021
    Publication date: December 2, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, Donna Gutterman, Carol O'Neill, Joseph Palumbo
  • TREATMENT OF SYNGAP1 ENCEPHALOPATHY
    Publication number: 20210077421
    Abstract: The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
    Type: Application
    Filed: September 16, 2020
    Publication date: March 18, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Terri Sebree, John Messenheimer, Donna Gutterman
  • PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME
    Publication number: 20210047284
    Abstract: Described herein are ?9-THC prodrugs, methods of making ?9-THC prodrugs, formulations comprising ?9-THC prodrugs and methods of using ?9-THC. One embodiment described herein relates to the transdermal administration of a ?9-THC prodrug for treating and preventing diseases and/or disorders.
    Type: Application
    Filed: August 28, 2020
    Publication date: February 18, 2021
    Applicant: ZYNERBA PHARMACEUTICALS, INC.
    Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammell, Jeffrey Lynn Howard